Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.8)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 3, March, p. 391–399

doi: 10.17219/acem/68440

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Immunomodulatory properties of human recombinant lactoferrin in mice: Implications for therapeutic use in humans

Jolanta Artym1,C,E,F, Maja Kocięba1,B,E, Ewa Zaczyńska1,B,C,F, Barbara Adamik2,B,C,E,F, Andrzej Kübler2,B,E, Michał Zimecki1,A,B,C,D,E,F, Marian Kruzel3,A,F

1 Laboratory of Immunobiology, Institute of Immunology and Experimental Therapy, Wrocław, Poland

2 Department of Anesthesiology and Intensive Therapy, Wroclaw Medical University, Poland

3 University of Texas, Houston Medical School, USA

Abstract

Background. Trauma and major surgery cause extensive immune hyporeactivity in patients. Thus, the preventive, preoperative application of immunoregulatory therapeutics may normalize this immune reactivity and decrease morbidity and mortality in these subjects.
Objectives. The aim of this study was to investigate the immunomodulatory actions of recombinant human lactoferrin (rhLF) in mice, and to relate these effects to in vitro actions of rhLF on tumor necrosis factor alpha (TNF-α) production in lipopolysaccharide-stimulated whole blood cell cultures (LPS-stimulated WBCC) from patients admitted to intensive care units.
Material and Methods. BALB/c and CBA mice were used. rhLF was tested for allergic response to ovalbumin (OVA), delayed-type hypersensitivity (DTH) to OVA, and carrageenan-induced inflammation in an air pouch. Blood samples from 30 patients diagnosed with severe sepsis/septic shock (Apache II 21 ±1, mortality rate 40%) were collected on days 1, 3 and 5 of observation. The effects of rhLF on LPS-induced TNF-α production were measured in WBCCs.
Results. Recombinant human lactoferrin reduced the parameters of OVA-induced inflammation and inhibited the elicitation phase of DTH and carrageenan-induced inflammation in mice. The majority of patients from whom whole blood cell cultures (WBCC) were established showed a strong hyporeactivity to LPS upon admission. rhLF exerted differential effects on the production of LPS-induced TNF-α in those cultures on days 1, 3 and 5 of observation. Cytokine production was upregulated only in patients with sustained anergy to LPS, and inhibited or unchanged in moderately reactive patients.
Conclusion. Evidence for the potential preventive or therapeutic utility of rhLF in patients with impaired immune reactivity has been demonstrated.

Key words

human recombinant lactoferrin, mice, pleurisy, septic patients, tumor necrosis factor alpha

References (32)

  1. Börgermann J, Friedrich I, Flohé S, et al. Tumor necrosis factor-alpha production in whole blood after cardiopulmonary bypass: Downreg- ulation caused by circulating cytokine-inhibitory activities. J Thorac Cardiovasc Surg. 2002;124:608–617.
  2. Houdijk AP, Meijer C, Cuesta MA, Meyer S, Van Leeuwen PA. Periop- erative anti-endotoxin strategies. Scand J Gastroenterol. 1997;32(222):
  3. Almansa R, Wain J, Tamayo E, et al. Immunological monitoring to pre- vent and treat sepsis. Crit Care. 2013;17:109.
  4. García-Montoya IA, Cendón TS, Arévalo-Gallegos S, Rascón-Cruz Q. Lactoferrin a multiple bioactive protein: An overview. Biochim Bio- phys Acta. 2012;1820:226–236.
  5. Legrand D, Elass E, Carpentier M, Mazurier J. Lactoferrin: A modula- tor of immune and inflammatory responses. Cell Mol Life Sci. 2005;62:
  6. Berkestedt I, Herwald H, Ljunggren L, Nelson A, Bodelsson M. Ele- vated plasma levels of antimicrobial polypeptides in patients with severe sepsis. J Innate Immun. 2010;2:478–482.
  7. Modig J, Samuelsson T, Hällgren R. The predictive and discriminative value of biologically active products of eosinophils, neutrophils and complement in bronchoalveolar lavage and blood in patients with adult respiratory distress syndrome. Resuscitation. 1986;14:121–134.
  8. Hällgren R, Venge P, Wikström B. Hemodialysis-induced increase in serum lactoferrin and serum eosinophil cationic protein as signs of local neutrophil and eosinophil degranulation. Nephron. 1981;29:
  9. Stammers AH, Christensen K A, Lynch J, Zavadil DP, Deptula JJ, Sydzyik RT. Quantitative evaluation of heparin-coated versus non- heparin-coated bypass circuits during cardiopulmonary bypass. J Extra Corpor Technol. 1999;31:135–141.
  10. Edeleva NV, Sergeeva TV, Nemtsova ER, Shcherbitskaia I, Yakubovs- kaia RI, Osipova NA. Antioxidants ceruloplasmin and lactoferrin in the prevention and treatment of postoperative complications in cancer patients. Anesteziol Reanimatol. 2001;5:61–64.
  11. Chissov VI, Yakubovskaia RI, Nemtsova ER, et al. Antioxidants treat- ment of severe post-operative proinflammatory and septic compli- cations. Khirurgiia. 2008;11:14–19.
  12. Guntupalli K, Dean N, Morris PE, et al. For the TLF LF-0801 Investi- gator Group: A phase 2 randomized, double-blind, placebo-con- trolled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med. 2013;41:706–716.
  13. Akin IM, Atasay B, Dogu F, et al. Oral lactoferrin to prevent noso- comial sepsis and necrotizing enterocolitis of premature neonates and effect on T-regulatory cells. Am J Perinatol. 2014;31:1111–1120.
  14. Adamik B, Zimecki M, Właszczyk A, Berezowicz P, Kübler A. Lactofer- rin effects on the in vitro immune response in critically ill patients. Arch Immunol Ther Exp. 1998;46:169–176.
  15. Właszczyk A, Zimecki M, Adamik B, Durek G, Kübler A. Immunological status of patients subjected to cardiac surgery: Effect of lactoferrin on proliferation and production of interleukin 6 and tumor necro- sis factor alpha by peripheral blood mononuclear cells in vitro. Arch Immunol Ther Exp. 1997;45:201–212.
  16. Zimecki M, Właszczyk A, Cheneau P, et al. Immunoregulatory effects of a nutritional preparation containing bovine lactoferrin taken oral- ly by healthy individuals. Arch Immunol Ther Exp. 1998;46:231–240.
  17. Zimecki M, Właszczyk A, Wojciechowski R, Dawiskiba J, Kruzel M. Lac- toferrin regulates the immune responses in post-surgical patients. Arch Immunol Ther Exp. 2001;49:325–333.
  18. Zimecki M, Właszczyk A, Zagulski T, Kübler A. Lactoferrin lowers serum interleukin 6 and tumor necrosis factor alpha levels in mice subjected to surgery. Arch Immunol Ther Exp. 1998;46:97–104.
  19. Ochoa TJ, Chea-Woo E, Baiocchi N, et al. Randomized double-blind controlled trial of bovine lactoferrin for prevention of diarrhea in chil- dren. J Pediatr. 2013;162:349–356.
  20. Takeuchi Y, Yamamura T, Takahashi S, et al. Long-term enteral immu- nonutrition containing lactoferrin in tube-fed bedridden patients: Immunological and nutritional status. J Am Coll Nutr. 2012; 31:206–213.
  21. Zavaleta N, Figueroa D, Rivera J, Sanchez J, Alfaro S, Lönnerdal B. Effi- cacy of rice-based oral rehydration solution containing recombinant human lactoferrin and lysozyme in Peruvian children with acute diar- rhea. J Pediatr Gastoenterol Nutr. 2007;44:258–264.
  22. Kruzel ML, Actor JK, Zimecki M, et al. Novel recombinant human lactoferrin: Differential activation of oxidative stress related gene expression. J Biotechnol. 2013;168:666–675.
  23. Zimecki M, Artym J, Kocięba M, Duk M, Kruzel ML. The effect of car- bohydrate moiety structure on the immunoregulatory activity of lac- toferrin in vitro. Cell Mol Biol Lett. 2014;19:284–296.
  24. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and sep- tic shock: 2008. Crit Care Med. 2008;36:296–327.
  25. Zimecki M, Artym J, Kocięba M, Kaleta-Kuratewicz K, Kruzel ML. Lac- toferrin restrains allergen-induced pleurisy in mice. Inflamm Res.
  26. La Manna G, Cappuccilli ML, Cianciolo G, et al. Cardiovascular disease in kidney transplant recipients: The prognostic value of inflammatory cytokine genotypes. Transplantation. 2010;89:1001–1008.
  27. Kruzel ML, Harari Y, Mailman D, Actor JK, Zimecki M. Differential ef fects of prophylactic, concurrent and therapeutic lactoferrin treatment on LPS-induced inflammatory responses in mice. Clin Exp Immunol. 2002;130:25–31.
  28. Ando K, Hasegawa K, Shindo K, et al. Human lactoferrin activates NF-kappaB through the Toll-like receptor 4 pathway while it inter- feres with the lipopolysaccharide-stimulated TLR4 signaling. FEBS J. 2010;277:2051–2066.
  29. Zimecki M, Artym J, Kocięba M. Endogenous steroids are respon- sible for lactoferrin-induced myelopoiesis in mice. Pharmacol Rep.
  30. Zimecki M, Międzybrodzki R, Szymaniec S. Oral treatment of rats with bovine lactoferrin inhibits carrageenan-induced inflammation; correlation with decreased cytokine production. Arch Immunol Ther Exp (Warsz). 1998;46:361–365.
  31. Strong VE, Mackrell PJ, Concannon EM, et al. Blocking prostaglan- din E2 after trauma attenuates pro-inflammatory cytokines and improves survival. Shock. 2000;14:374–379.
  32. Talukder MJ, Harada E. Bovine lactoferrin protects lipopolysaccha- ride-induced diarrhea modulating nitric oxide and prostaglandin E2 in mice. Can J Physiol Pharmacol. 2007;85:200–208.
© Wroclaw Medical University